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Abstract
Purpose The main objective of this study was
to evaluate if the 429T/C, 374T/A and 63 bp
deletion polymorphisms in the RAGE gene are
associated with diabetic retinopathy (DR)
among Type 2 diabetic subjects in a clinic-
based population from South India.
Methods We screened 149 normal glucose
tolerant subjects (NGT), 189 Type 2 diabetes
subjects without retinopathy (DM) and 190
subjects with DR for these polymorphisms
using the PCR-RFLP method. DR was
diagnosed by grading color fundus
photography. Logistic regression models were
used to evaluate the association of individual
polymorphisms with DR. Expectation–
maximization algorithms were implemented
in haplotype tests of association to examine
the combined effects of 429T/C and 374T/A
polymorphisms on DR.
Results The allelic frequencies of 429T are
0.83 in NGT, 0.84 in DM and 0.85 in DR
subjects, and that of 374T are 0.93 in NGT,
0.92 in DM and 0.88 in DR subjects. The 374
polymorphism was found to be associated
with non-proliferative retinopathy when this
subgroup was compared to the DM group
(OR¼ 1.814, 95% CI¼ 1.005–3.273). However,
this association was not obvious when both
the subphenotypes of DR (the
nonproliferative and proliferative DR groups)
were studied jointly. We found no evidence for
associations between the 429T/C
polymorphism and the DR phenotype. Finally,
extension to a 2-SNP haplotype did not reveal
any significant statistical difference between
the groups (P¼ 0.668).
Conclusion In this study, we found a modest
association with the 374T/A polymorphism
in the nonproliferative DR subgroup.
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Introduction
In individuals with diabetes, nonenzymatic
glycation of proteins leads to the formation of
advanced glycation end products (AGE) and
this process occurs at an accelerated rate in
chronic hyperglycaemia1, and also the levels are
found to be increased in complications of
diabetes, such as diabetic retinopathy (DR).2
AGE induces a variety of pathological changes,
such as increased basement membrane
thickening, arterial stiffness, and glomerular
sclerosis.3,4 AGEs bind to a specific receptor
known as receptor for advanced glycation end
products (RAGE). RAGE is expressed in many
of the cell types, such as the endothelial cells,
monocytes, and lymphocytes, including the beta
cells of the pancreas. RAGE-mediated signaling
leads to the activation of transcription factors,
such as NF-kB, AP-1, and STAT-1,5,6 the
adhesion molecules VCAM, ICAM, and tissue
factor,7,8 which promote a procoagulant state in
the microcapillaries of the retina. This results in
a hypoxic state that leads to the initiation of the
angiogenic process in proliferative DR.
The involvement of genetic factors in the
pathogenesis of DR has been supported by
studies that have demonstrated the familial
clustering of DR.9,10 Earlier studies performed
by Rema et al11 in a South Indian population
have shown that siblings of subjects with DR
were 3.5 times more likely to develop DR
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compared to siblings of subjects without DR, suggesting
a strong genetic component associated with the
development of DR in this population. Various candidate
genes have been tested for their association with DR,
which includes aldose reductase,12,13 nitric oxide
synthase,14,15 and MethylTetra Hydro Folate Reductase16
that have had conflicting reports in various populations.
Among many candidate genes that have been found to
be associated with retinopathy, the gene encoding RAGE
is of particular significance, because the RAGE-mediated
signaling induces key pathological changes in the
microvasculature leading to DR. A functional
polymorphism Gly82Ser in exon 3 has been previously
implicated in DR of which the Ser allele of this Gly82Ser
polymorphism has been shown to be protective in the
development of DR in the Asian-Indian population.17
Studies performed by Hudson et al18 have shown that
three polymorphisms located in the promoter region
(429TC and 374TA and 63 bp del) of the RAGE gene
are involved in the upregulation of the gene and thereby
could play a pivotal role in the pathogenesis leading to
DR. The 63 bp deletion polymorphism is in the region
encompassing the 374 region, and these promoter
polymorphisms exert their effect by affecting the
transcriptional regulation of the RAGE gene. The
association of these promoter polymorphisms has been
studied in various populations with respect to DR and
other diseases, but the results are conflicting.19–21
Although Indians have the largest number of diabetic
patients in the world,22,23 there is a paucity of literature
on the genetic factors contributing to DR in Indians.
In this study, we have examined 429 TC and 374 TA
promoter polymorphisms in relation to DR in South
Indian Type 2 diabetic subjects.
Subjects and methods
Three classes of study subjects were included as
described below. The first group referred to as the ‘DR’
group comprised of 190 diabetic subjects with any form
of retinopathy including (1) 133 nonproliferative diabetic
retinopathy (NPDR) subjects who had only NPDR
without diabetic macular oedema, duration of diabetes
410 years, and macroproteinuria o300 mg/day, and (2)
57 proliferative diabetic retinopathy (PDR) subjects with
macroproteinuria o300 mg/day. The second group
referred to as the ‘DM’ group consisted of 189 Type 2
diabetic subjects with a disease duration of 415 years,
and free from retinopathy and nephropathy. The ‘NGT’
group consisted of 149 normal glucose tolerant subjects
(NGT) over the age of 50 (thereby giving adequate time
to develop DM). Type 2 diabetic subjects with and
without DR for these first two categories were recruited
from patients who attended the out-patient clinic at the
Dr Mohan’s Diabetes Specialties Centre. To circumvent
the problem of population stratification, we performed a
case–control study at five unlinked marker loci believed
to be unrelated to the disease under study, but known to
have allelic diversity among different populations.24,25
The allele frequency difference between DM, DR, and
NGT subjects was not statistically significant at any of the
five loci.
To examine the association of polymorphisms in the
RAGE gene with DR, the main focus was to compare the
DR group consisting of NPDR and PDR subgroups both
individually and combined to the DM group, and to
further elucidate the role of these variants in Type 2
diabetes, the DM group was also compared with the NGT
group. Further comparison of the DR groups (both
individually and combined) to the NGT group was also
performed. Considering the association reported by
Hudson et al18 along with our sample size, our study
would have had a power of 91% to detect a similar
association.
Informed consent was obtained from all study subjects
as per the protocol approved by the Madras Diabetes
Research Foundation Institutional Ethics Review Board.
Biochemical estimations
A fasting blood sample was taken and serum separated
and stored at 701C until the assays were performed.
Biochemical analyses were performed on a Hitachi-912
Autoanalyser (Hitachi, Germany) using kits supplied by
Roche Diagnostics (Mannheim, Germany). Fasting
plasma glucose (GOD-POD method), serum cholesterol
(CHOD-PAP method), serum triglycerides (GPO-PAP
method), and HDL cholesterol (Direct method-
polyethylene glycol-pretreated enzymes) were measured.
Low-density lipoprotein (LDL) cholesterol was
calculated using the Friedewald formula.26 Glycated
haemoglobin (HbA1C) was estimated by high-
performance liquid chromatography using the Variant
machine (Bio-Rad, Hercules, CA, USA).
Urine samples were collected in the early morning
after an overnight fast. Urinary protein was measured on
spot urine by sulphosalicylic acid technique. Expected
protein excretion was calculated by the protein/
creatinine ratio method and overt proteinuria was
defined as Z300 mg/day.27
DR diagnosis
DR was diagnosed by retinal examination and
documented by 35 mm colour photography. For retinal
examination, the pupils were dilated by instilling one
drop each of phenylephrine 10% and tropicamide 1% in
both eyes, and the drops were repeated until the best
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possible mydriasis was obtained. Four-field colour
retinal photography was carried out by a trained
photographer with a Zeiss FF 450 plus camera using
35 mm colour transparencies. The four fields taken were
stereoscopic pictures of the macula, disc, superior
temporal, and inferior temporal quadrants. If
photography of a particular eye or any field was not
possible due to inadequate dilatation, inability to
cooperate or opacities of the media, these were specified
as missing eye or fields.
Grading of retinal photographs were performed using
an identification number and assessed in a masked
manner in order to minimize any possible bias. The
photographs were graded for severity of retinopathy
against standard photographs of the Early Treatment
Diabetic Retinopathy Study (ETDRS) grading system.28
The eye with the higher grade of retinopathy was taken
as the final diagnosis for that individual.
PCR-RFLP
Human genomic DNA was extracted using the phenol–
chloroform method. PCR-RFLP genotyping was carried
out as described.18 PCR consisted of 100–150 ng of DNA
denaturing at 941C, annealing at 561C, extension at 721C
for 30 cycles, followed by a final extension at 721C for
5 min in a 50 ml reaction. The PCR products were then
digested with Alu I (New England Bio Labs) at 371C for
6 h for 429 T/C polymorphism and Tsp509 I (New
England Bio Labs) at 651C for 16 h for 374 T/A
polymorphism.18 The restricted products were separated
in a 3% agarose gel and visualized using ethidium
bromide staining.
Statistical analysis
For this case–control study design, independent sample
t-tests were used to evaluate differences in the
quantitative traits between the various study groups
using the SPSS computer program (version 10). Traits
were log transformed to approximate a Gaussian
distribution where required, and adjusted for the
covariates of age and sex as necessary. Allele and
genotype frequencies, logistic regressions for odds ratios
(OR), and w2 tests were evaluated to test for associations
at the single SNP level. Hardy Weinberg equilibrium was
evaluated using w2 tests (in Excel 2003), and linkage
disequilibrium was evaluated using Haploview.29
Groupwise haplotype frequencies were generated using
the expectation–maximization (EM) algorithm as
described by Fallin et al.30 Haplotype frequencies and w2
values were calculated for each individual haplotype vs
all others, and empiric significance was assessed using
10 000 permutations of the observed data. The ‘omnibus
test’ was also performed to detect differences in overall
haplotype frequency profiles between case–control
groups.30 The haplotype analyses were performed using
SNPEM.30
Results
We screened the promoter region of the RAGE gene for
two functional promoter polymorphisms, namely the
Table 1 Comparison of clinical features between normal glucose tolerant subjects (NGT), diabetic subjects with retinopathy (DR), and
diabetic subjects without retinopathy (DM)
DR
Clinical characteristics NGT n¼ 149 DM n¼ 189 NPDR n¼ 133 PDR n¼ 57
Age in years 59 (8) 63 (9)*** 59 (8)### 59 (8)###
Males (n, %) 77 (52%) 131 (69%)** 65 (49%)### 40 (70%)###
Duration in years F 21 (5) 20 (6) 20 (8)
HbA1C as % 5.8 (0.5) 8.1 (1.6)*** 8.6 (1.9)***,# 8.9 (1.7)***,#
FBS (mg/dl) 86 (10) 154 (60)*** 167 (68)*** 161 (61)***
PPBS (mg/dl) F 234 (85) 248 (76) 242 (82)
SBP (mmHg)a 126 (19) 133 (15)* 137 (18)***,# 139 (17)***,#
DBP (mmHg)b 77 (10) 80 (11) 82 (14) 84 (22)
Cholesterol (mg/dl)a 190 (37) 184 (37) 189 (53) 178 (47)
Triglycerides (mg/dl)a,b 115 (55) 147 (95)*** 178 (126)*** 139 (72)***
Unless otherwise stated, values are represented as mean (SD).
*Po0.05, **Po0.01, ***Po0.001 when compared with nondiabetic subjects.
#Po0.05, ##Po0.01, ###Po0.001 when compared with diabetic subjects.
aData adjusted for age and/or gender.
bStatistical analysis was performed on log transformed data.
FBS¼ fasting blood sugar; PPBS¼postprandial blood sugar; SBP¼ systolic blood pressure; DBP¼diastolic blood pressure.
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429 T/C and 374 T/A, in 529 unrelated subjects of
South Indian origin. The clinical characteristics of the
three study groups are shown in Table 1. Age, HbA1C,
fasting blood sugar, systolic blood pressure, and
triglycerides were significantly associated with diabetes
(comparing the DR and DM groups to the NGT group).
Systolic blood pressure, HbA1C, and male gender were
nominally associated with DR (Po0.05 comparing the
DR group to the DM group), and the DM subjects were
significantly older (Po0.001).
The overall minor allele frequency in all study subjects
was 16% for the 429(C) polymorphism and 9% for the
374(A) polymorphism. Both SNPs were in Hardy
Weinberg equilibrium, and linkage disequilibrium (LD)
between them was moderate (D0 ¼ 0.74, R2¼ 0.02, 95% CI
for D0: 0.27–0.93). The two individual SNPs were not
associated with DR or diabetes at the allelic level: P-value
for DM vs NGT was 0.729, for DR vs DM was 0.101, and
DR vs NGT was 0.064 for 374T/A, and 0.719, 0.668,
0.444 for the same three comparisons for 429T/C,
respectively.
In the evaluation of associations at the genotype level,
the rare homozygous group was collapsed with the
heterozygous group for both polymorphisms (Table 2).
Subjects with the 63 bp deletion were first excluded from
these genotype analyses for the 374T/A
polymorphism, as all these individuals had only a
single copy of this polymorphism. Only a marginal
association was observed for the 374T/A
polymorphism in the comparison of the NPDR
subjects to the DM group (OR¼ 1.814, P¼ 0.048, 95%
CI¼ 1.005–3.273), and no association was detected
comparing the PDR and DM groups (OR¼ 0.990,
P¼ 0.982, 95% CI¼ 0.419–2.336). No associations were
detected for the 429T/C polymorphisms (Table 2).
Tests of association were repeated adjusting for age
and gender, and no difference was observed even after
adjustment. Subsequent comparison of these groups to
Table 2 Association between the 429 and 374 promoter polymorphisms in the RAGE gene and diabetic retinopathy at the
genotype level
DR
Genotype NGT N¼ 149 DM N¼ 189 ALL DR N¼ 190 NPDR N¼ 133 PDR N¼ 57
374 T/A Polymorphism
TT 117 (79%) 148 (78%) 137 (72%) 91 (68%) 46 (81%)
TA 20 (13%) 24 (13%) 33 (17%) 26 (20%) 7 (12%)
AAa 0 2 (1%) 4 (2%) 3 (2%) 1 (2%)
63 bp del 12 (8%) 15 (8%) 16 (8%) 13 (10%) 3 (5%)
Odds ratiob 95% confidence interval P-valuec
NPDR vs DMref 1.814 1.005–3.273 0.048
PDR vs DMref 0.990 0.419–2.336 0.982
DR vs DMref 1.537 0.885–2.672 0.127
DM vs NGTref 1.028 0.547–1.932 0.932
DR vs NGTref 1.580 0.869–2.871 0.133
NPDR vs NGTref 1.864 0.991–3.508 0.053
PDR vs NGTref 1.017 0.419–2.473 0.970
429 T/C Polymorphism
TT 97 (65%) 130 (69%) 132(69%) 95(71%) 37(65%)
TC 52 (35%) 56 (30%) 58 (31%) 38(29%) 20(35%)
CCa 0 3 (1%) 0 0 0
Odds ratiob 95% confidence interval P-valuec
NPDR vs DMref 0.881 0.542–1.433 0.611
PDR vs DMref 1.191 0.637–2.225 0.584
DR vs DMref 0.968 0.626–1.497 0.884
DM vs NGTref 0.847 0.536–1.336 0.474
DR vs NGTref 0.820 0.519–1.294 0.394
NPDR vs NGTref 0.746 0.450–1.236 0.256
PDR vs NGTref 1.008 0.532–1.912 0.980
Percentages reflect column totals. ref¼Reference baseline group.
aHomozygote of the minor allele was collapsed with the heterozygote due to small sample sizes (TT is the baseline group).
bSubjects with the 63 bp deletion were excluded from this analysis.
cTests of association were repeated adjusting for age and gender, and no difference was observed even after adjustment.
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the NGT group revealed no evidence for association (see
Table 2). Extension to the two-SNP haplotype also
showed no association between these promoter
polymorphisms and the DR phenotype in our data
(P¼ 0.668) (Table 3).
The 63 bp deletion polymorphism was found only in
the heterozygous state in all the study subjects when
present. This 63 bp deletion polymorphism was also
found to be similar in all the three groups, which were
present in 12 NGT, 15 DM, and 16 DR subjects. We
examined the effect of this 63 bp deletion in the genotype
and haplotype analyses by coding all subjects with the
deletion as heterozygous at the 374 polymorphism.
Here, the genotype analysis once again provided only
marginal evidence in the comparison of the NPDR
and DM groups (OR¼ 1.666, P¼ 0.047, 95% CI¼
1.007–2.756), but there was no evidence for any
association with DR at the haplotype level (P¼ 0.589,
data not shown).
Discussion
The AGE–RAGE pathway has been extensively studied
in the context of diabetic vascular disease. Variations in
the RAGE gene have been identified and screened for
association with DR and other diseases.31–33 Of the many
polymorphisms that have been screened, the 429 and
374 are considered important, since these
polymorphisms are reported to increase the RAGE gene
transcript, which will augment increased AGE binding to
cells and as a result lead to an altered signaling cascade.
The G82S polymorphism has also been studied in
various populations, which is yet another important
polymorphism previously studied in this population.17
Here, we screened for the first time the 429 and 374
promoter polymorphisms to look for their association
with DR in South Indian subjects.
As expected, several of the biochemical parameters
assayed showed significant differences between the
study groups, including age, HbA1c, fasting blood sugar,
systolic blood pressure, and triglycerides. The difference
in age is due to our selection criteria for DM subjects,
which necessitates a 15-year duration of diabetes without
any form of retinopathy. The other clinical parameters
with significant differences are well-established risk
factors for the development of DR.
Association results from studies performed on the
374 and 429 RAGE polymorphisms have not been
consistent between different populations. Although
studies in UK-based Caucasian populations have
associated the 429 T/C polymorphism with
retinopathy13 and the 374 polymorphism with CAD
and proteinuria in Finnish Type 1 diabetic subjects,19 we
did not find evidence for association of DR with either
the 429 T/C or the 374 T/A polymorphism in our
data, despite a larger sample size with adequate power to
detect associations at the reported levels. Upon
stratifying the DR subjects into NPDR and PDR groups,
while we observed association with the 374T/A
polymorphism for the NPDR group, this was marginally
significant (P¼ 0.048), and hence should be interpreted
with caution, especially considering the multiple tests
carried out as part of these analyses. However, glycation
is a process that takes place when diabetes sets in and the
modified proteins bind to the RAGE on the retinal
endothelial cells. This triggers a signaling cascade,
leading to the release of proinflammatory cytokines and
adhesion proteins that favour thrombosis and eventually
capillary leakage and occlusion resulting in NPDR. In
this context, this 374 polymorphism assumes
significance given the induction of the RAGE gene by
AGE.
Given the presence of LD between these
polymorphisms as has been reported in other studies
as well,18,19 we also performed haplotype tests for
association which also yielded no evidence for
association. In this study, we also compared the allele
frequencies between the nondiabetics and the DM group,
and also found them to be similar.
In conclusion, our results show an association of 374
T/A polymorphism with NPDR, which is inconsistent
to the Slovakian study, and the Chinese study which
did not show any association between these promoter
polymorphisms and DR.20,21 Other RAGE gene
polymorphisms such as G82S, G1704T, A2484G,
and G2245A, which have been studied extensively in
different populations,32–37 need to be studied in this
population to understand the impact of these variations
on the onset and progression of DR. Ethnic variations,
if any, that may have been present in the study subjects
were tested using genomic controls that did not
show allele frequency variation among the groups,
suggesting strongly that these results are not an
artefact due to population substructuring. Studies
on the RAGE protein expression in the retinal endothelial
Table 3 Association analysis of haplotypes constructed across
the 374 and 429 polymorphisms for diabetic retinopathy
374/429 Haplotype DR (%) DM (%) P-value*
T-T 74 76 0.270
C-T 15 16 0.624
T-A 10 8 0.232
C-A 1 0.3 0.874
Omnibus P-value**¼ 0.668
*P-value for each haplotype vs all others combined, ** omnibus P-value
for the overall test of association.
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cells and the serum measurement of AGE levels in
these patients will give further insight into the
influence of AGE interaction with this promoter
polymorphism leading to vascular complications of
diabetes.
Acknowledgements
This study was supported by a Grant from the
Department of Biotechnology (DBT), New Delhi, India.
This research was supported in part by the Intramural
Research Program of the National Human Genome
Research Institute, National Institutes of Health. The
authors are also thankful to Ms P Gayathri for her help in
recruiting the study subjects. The authors take
responsibility for the integrity of the data and the
accuracy of the data analysis.
References
1 Ceramin A, Vlassara H, Brownlee M. Role of AGE’s in
complications of diabetes. Diabetes Care 1988; 11: 73–79.
2 Sampathkumar R, Balasubramanyam M, Premanand C,
Rema M, Mohan V. Novel Advanced Glycation Index (AGI)
and its association with diabetes and Microangiopathy.
Metabolism 2005; 54(8): 1002–1007.
3 Brownlee M, Cerami A, Vlassara H. Advanced
glycosylation end products in tissue and the biochemical
basis of diabetic complications. N Engl J Med 1988; 318(20):
1315–1321.
4 Horie K, Miyata T, Maeda K, Miyata S, Sugiyanma S,
Sakai H et al. Immunohistochemical colocalization of
glycoxidation products and lipid peroxidation products
in diabetic renal glomerular lesions. Implication for
glycoxidative stress in the pathogenesis of diabetic
nephropathy. J Clin Invest 1997; 100: 2995–3004.
5 Bierhaus A, Chevion S, Chevion M, Hofmann M,
Quehenberger P, Illmer T et al. Advanced glycation end
products AGEs induced activation of NF-kB is suppressed
by a-lipoic acid in cultured endothelial cells. Diabetes 1997;
46: 1481–1490.
6 Huang JS, Guh JY, Hung WC, Yang ML, Lai YH, Chen HC
et al. Role of the Janus kinase (JAK)/signal transducters and
activators of transcription (STAT) cascade in advanced
glycation end-product-induced cellular mitogenesis in
NRK-49F cells. Biochem J 1999; 342(Part1): 231–238.
7 Vlassara H, Fuh H, Donnelly T, Cybulsky M. Advanced
glycation endproducts promote adhesion molecule VCAM-
1, ICAM-1 expression and atheroma formation in normal
rabbits. Mol Med 1995; 1: 447–456. 196.
8 Bierhaus A, Illmer T, Kasper M, Luther T, Quehenberger P,
Tritschler H et al. Advanced glycation endproducts AGEs
mediated induction of tissue factor in cultured endothelial
cells is dependent on RAGE. Circulation 1997; 96: 2262–2271.
9 The Diabetes Control and Complications Trial Research
Group. Clustering of long-term complications in families
with diabetes in the diabetes control and complications trial.
Diabetes 1997; 46(11): 1829–1839.
10 Pyke DA, Tattersall RB. Diabetic retinopathy in identical
twins. Diabetes 1972; 22: 613–618.
11 Rema M, Saravanan G, Deepa R, Mohan V. Familial
clustering of diabetic retinopathy in South Indian Type 2
diabetic patients. Diabet Med 2002; 19(11): 910–916.
12 Santos KG, Tschiedel B, Schneider J, Souto K, Roisenberg I.
Diabetic retinopathy in Euro-Brazilian type 2 diabetic
patients: relationship with polymorphisms in the aldose
reductase, the plasminogen activator inhibitor-1 and the
methylenetetrahydrofolate reductase genes. Diabetes Res
Clin Pract 2003; 61(2): 133–136.
13 Kumaramanickavel G, Sripriya S, Ramprasad VL, Upadyay
NK, Paul PG, Sharma T. Z-2 aldose reductase allele and
diabetic retinopathy in India. Ophthalmic Genet 2003; 24(1):
41–48.
14 Taverna MJ, Elgrably F, Selmi H, Selam JL, Slama G. The
T-786C and C774T endothelial nitric oxide synthase gene
polymorphisms independently affect the onset pattern of
severe diabetic retinopathy. Nitric Oxide 2005; 13(1): 88–92.
15 Fujita H, Narita T, Meguro H, Ishii T, Hanyu O, Suzuki K
et al. Lack of association between an ecNOS gene
polymorphism and diabetic nephropathy in type 2 diabetic
patients with proliferative diabetic retinopathy. Horm Metab
Res 2000; 32(2): 80–83.
16 Zintzaras E, Chatzoulis DZ, Karabatsas CH, Stefanidis I.
The relationship between C677T methylenetetrahydrofolate
reductase gene polymorphism and retinopathy in type 2
diabetes: a meta-analysis. J Hum Genet 2005; 50(6): 267–275.
E-pub 2005 May 18.
17 Kumaramanickavel G, Ramprasad VL, Sripriya S,
Upadyay NK, Paul PG, Sharma T et al. Association of
Gly82Ser polymorphism in the RAGE gene with diabetic
retinopathy in type II diabetic Asian Indian patients.
J Diabetes Complications 2002; 16(6): 391–394.
18 Hudson BI, Stickland MH, Futers TS, Grant PJ. Effects of
novel polymorphisms in the RAGE gene on transcriptional
regulation and their association with diabetic retinopathy.
Diabetes 2001; 50(6): 1505–1511.
19 Pettersson-Fernholm K, Forsblom C, Hudson BI et al.
Finn-Diane Study Group. The functional 374 T/A RAGE
gene polymorphism is associated with proteinuria and
cardiovascular disease in type 1 diabetic patients. Diabetes
2003; 52(3): 891–894.
20 Globocnik Petrovic M, Steblovnik K, Peterlin B et al. The
429 T/C and 374 T/A gene polymorphisms of the
receptor of advanced glycation end products gene are not
risk factors for diabetic retinopathy in Caucasians with type
2 diabetes. Klin Monatsbl Augenheilkd 2003; 220(12): 873–876.
21 JiXiong X, BiLin X, MingGong Y, ShuQin L. 429T/C and
374T/A polymorphisms of RAGE gene promoter are not
associated with diabetic retinopathy in Chinese patients
with type 2 diabetes. Diabetes Care 2003; 26(9): 2696–2697.
22 King H, Aubert R, Herman W. Global burden of diabetes,
1995–2025. Prevalence, numericalestimates and projections.
Diabetes Care 1998; 21: 1414–1431.
23 Wild S, Roglic G, Green A, Sicree R, King H. Global
prevalence of diabetes: estimates for the year 2000 and
projections for 2030. Diabetes Care 2004; 27(5): 1047–1053.
24 Basu A, Mukherjee N, Roy S, Sengupta S, Banerjee S,
Chakraborty M et al. Ethnic India: a genomic view, with
special reference to peopling and structure. Genome Res
2003; 13: 2277–2290.
25 Devlin B, Roeder K, Wasserman L. Genomic control, a new
approach to genetic-based association studies. Theor Popul
Biol 2001; 60: 155–166.
Rage gene promoter polymorphisms and DR
S Ramprasad et al
400
Eye
26 Friedewald WT, Levy RI, Fredrickson DS. Estimation of low
density lipoprotein cholesterol without the use of the
preparative ultracentrifuge. Clin Chem 1972; 18: 499–502.
27 Varghese A, Deepa R, Rema M, Mohan V. Prevalence of
microalbuminuria in Type 2 diabetes mellitus at a diabetes
centre in Southern India. Postgraduate Med J 2001; 77:
399–402.
28 Early Treatment of Diabetic Retinopathy Study Research
Group. Grading diabetic retinopathy from stereoscopic
colour fundus photographs – an extension of the modified
Airlie House Classification. ETDRS Report 10.
Ophthalmology 1991; 98: 786–806.
29 Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis
and visualization of LD and haplotype maps. Bioinformatics
2005; 21: 263–265.
30 Fallin D, Schork NJ. Accuracy of haplotype frequency
estimation for biallelic loci, via the expectation-
maximization algorithm for unphased diploid genotype
data. Am J Hum Genet 2000; 67: 947–959.
31 Poirier O, Nicaud V, Vionnet N, Raoux S, Tarnow L,
Vlassara H et al. Polymorphism screening of four genes
encoding advanced glycation end-product putative
receptors. Association study with nephropathy in type 1
diabetic patients. Diabetes 2001; 50(5): 1214–1218.
32 Falcone C, Campo I, Emanuele E, Buzzi MP, Geroldi D,
Belvito C et al. 374T/A polymorphism of the RAGE gene
promoter in relation to severity of coronary atherosclerosis.
Clin Chim Acta 2005; 354(1–2): 111–116. E-pub 2005 Jan 13.
33 Holla LI, Kankova K, Fassmann A, Buckova D, Halabala T,
Znojil V et al. Distribution of the receptor for advanced
glycation end products gene polymorphisms in patients
with chronic periodontitis: a preliminary study. J Periodontol
2001; 72(12): 1742–1746.
34 Prevost G, Fajardy I, Besmond C, Balkau B, Tichet J,
Fontaine P et al. The Genediab and D.E.S.I.R studies.
Polymorphisms of the receptor of advanced glycation
endproducts (RAGE) and the development of nephropathy
in type 1 diabetic patients. Diabetes Metab 2005; 31(1): 35–39.
35 Yoshioka K, Yoshida T, Takakura Y, Umekawa T, Kogure A,
Toda H et al. Association study of G1704T and G82S
polymorphisms of RAGE gene for microalbuminuria in
Japanese type 2 diabetic patients. Metabolism 2005; 54(4):
488–491.
36 Kankova K, Stejskalova A, Hertlova M, Znojil V. Haplotype
analysis of the RAGE gene: identification of a haplotype
marker for diabetic nephropathy in type 2 diabetes mellitus.
Nephrol Dial Transplant 2005; 20(6): 1093–1102. E-pub 2005
Mar 24.
37 Matsunaga-Irie S, Maruyama T, Yamamoto Y, Motohashi Y,
Hirose H, Shimada A et al. Relation between development
of nephropathy and the p22phox C242T and receptor for
advanced glycation end product G1704T gene
polymorphisms in type 2 diabetic patients. Diabetes Care
2004; 27(2): 303–307.
Rage gene promoter polymorphisms and DR
S Ramprasad et al
401
Eye
